This inventor holds 7 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: University System of Maryland, Sarepta Therapeutics, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2016-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
7 out of 2,029 
5 out of 127 
5 out of 3,697 
Years Active: 2016-2025
Title: Inventor Spotlight: Kan Cao
Introduction
Kan Cao, an accomplished inventor based in Bowie, MD, has made significant contributions to the field of biotechnology through his innovative work. With a total of 6 patents, his research focuses primarily on targeted therapies that address genetic disorders. His inventive journey reflects a commitment to advancing medical science and improving patient outcomes.
Latest Patents
Kan Cao's latest patents include groundbreaking work on oligonucleotide analogues targeting human LMNA. These patents provide LMNA-targeted antisense oligonucleotides designed to reduce the expression of aberrantly spliced LMNA mRNA isoforms that encode progerin. This research has the potential to offer new avenues for the treatment of conditions associated with LMNA mutations, representing a crucial step forward in therapeutic approaches.
Career Highlights
Cao has held pivotal roles at reputed institutions, including the University of Maryland and Sarepta Therapeutics, Inc. His work has not only resulted in numerous patents but has also placed him at the forefront of research in genetic therapies. His career demonstrates a balance of academic rigor and practical application in the field of biotechnology.
Collaborations
Throughout his career, Kan Cao has collaborated with esteemed professionals, including Ryszard M. Kole and Francis S. Collins. These partnerships highlight the interdisciplinary nature of his work and contribute to the advancements in understanding and treating genetic disorders. The synergy between these collaborators enhances the impact of their research on the scientific community.
Conclusion
Kan Cao's innovative contributions to biotechnology and his advancement of genetic therapies exemplify the essential role of inventors in medicine. With a commitment to improving the lives of patients through his work, Kan continues to inspire future advancements in the field. His ongoing research and collaboration with leading experts reinforce the importance of innovation in addressing complex medical challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile